VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

B. burgdorferi DbpA and OspA Protein Vaccine B. burgdorferi DbpA Protein Vaccine B. burgdorferi DNA vaccine encoding strain B31 OspA B. burgdorferi DNA vaccine pCMV-ZS7/TPA encoding OspC from Borrelia burgdorferi sensu lato B. burgdorferi OspA Protein Vaccine B. burgdorferi OspB Protein Vaccine B. burgdorferi OspC Protein Vaccine Borrelia burgdorferi fla mutant vaccine
Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information Vaccine Information
  • Vaccine Ontology ID: VO_0004188
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: DbpAN40-OspAN40
  • DbpA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • OspA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004027
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: The recombinant fusion lipoprotein pp2:DbpAN40(His)6 (DbpAN40) (Hanson et al., 2000).
  • DbpA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004513
  • Type: DNA vaccine
  • Status: Research
  • OspA gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: VR2210 (Luke et al., 1997)
  • Immunization Route: Intramuscular injection (i.m.)
  • Vaccine Ontology ID: VO_0004413
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • OspC gene engineering:
    • Type: DNA vaccine construction
    • Detailed Gene Information: Click Here.
  • Vector: pCMV-TPA/ZS7 (Scheiblhofer et al., 2003)
  • Immunization Route: Intradermal injection (i.d.)
  • Vaccine Ontology ID: VO_0004028
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant OspA protein
  • OspA gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004029
  • Type: Recombinant vector vaccine
  • Status: Research
  • Antigen: Recombinant OspB protein
  • OspB gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0004030
  • Type: Subunit vaccine
  • Status: Research
  • Antigen: Recombinant OspC protein
  • OspC gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: complete Freunds adjuvant
  • Adjuvant: incomplete Freunds adjuvant
  • Immunization Route: Intraperitoneal injection (i.p.)
  • Vaccine Ontology ID: VO_0002809
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • fla gene engineering:
    • Type: Gene mutation
    • Description: This fla mutant is from Borrelia burgdorferi (Sadziene et al., 1996).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intradermal injection (i.d.)
Host Response Host Response Host Response Host Response Host Response Host Response Host Response Host Response

Mouse Response

  • Host Strain: C3H/HeJ
  • Vaccination Protocol: Mice were immunized by intraperitoneal injection of 10 μg of DbpAN40, 10 μg of OspAN40, 5 μg of DbpAN40 plus 5 μg of OspAN40, or 2.5 μg of E. coli protein extract with complete Freund's adjuvant and then, 4 weeks later, were given a second immunization of protein in incomplete Freund's adjuvant (Hanson et al., 2000).
  • Challenge Protocol: At week 6, five of the mice in each immunization group were challenged by subcutaneous injection, into the dorsolateral thorax, of cloned B. burgdorferi N40 (Hanson et al., 2000).
  • Efficacy: All mice immunized with the combined DbpAN40-OspAN40 vaccine (5 μg of each antigen) were protected against even the highest challenge dose of 106 spirochetes (Hanson et al., 2000).

Mouse Response

  • Host Strain: C3H/HeJ
  • Vaccination Protocol: Mice were immunized by intraperitoneal injection of 10 μg of DbpAN40, 10 μg of OspAN40, 5 μg of DbpAN40 plus 5 μg of OspAN40, or 2.5 μg of E. coli protein extract with complete Freund's adjuvant and then, 4 weeks later, were given a second immunization of protein in incomplete Freund's adjuvant (Hanson et al., 2000).
  • Challenge Protocol: At week 6, five of the mice in each immunization group were challenged by subcutaneous injection, into the dorsolateral thorax, of cloned B. burgdorferi N40 (Hanson et al., 2000).
  • Efficacy: Mice immunized with recombinant DbpA protein are protected against challenge with Borrelia burgdorferi. Nearly all mice immunized with 10 μg of DbpAN40 were protected from challenge with 103 or 104 spirochetes (Hanson et al., 2000).

Mouse Response

  • Vaccination Protocol: Female C3H/HeN mice (6-10 weeks old) were injected with plasmid diluted in sterile 0.9% saline. Each mouse received intramuscular injections into left and right rectus femoris muscles with 50 J-lg of plasmid in 50 J-lL of saline. For immunization with protein, mice were injected in the back with purified B31 rOspA lipoprotein (Luke et al., 1997).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Sera from mice immunized with the ospA-bearing plasmid DNA had high levels of antibody that recognized both native and rOspA lipoprotein (Luke et al., 1997).
  • Challenge Protocol: Mice were challenged intradermally by injecting 100 x ID50 of the infectious isolate at the base of the tail (Luke et al., 1997).
  • Efficacy: Immunization with VR2210 protected 100% of mice against infection with Sh-2-82 or N40, 2 infectious strains of B. burgdorferi (Luke et al., 1997).

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Both i.d. injection and gene-gun application of plasmid DNA encoding the ospC gene induced a reliable humoral response with high antibody titers, antigen-specific cellular responses and, most importantly, provided effective protection (Scheiblhofer et al., 2003).
  • Challenge Protocol: Control groups received challenge doses B. burgdorferi strain ZS7 of 104, 103, 102, and 10 live spirochetes per animal (Scheiblhofer et al., 2003).
  • Efficacy: The protection rate after challenge with 10 B. burgdorferi organisms per mouse was between 80% and 100% for all groups. These results demonstrate that a DNA vaccine encoding OspC of B. burgdorferi is suitable for inducing protection against Lyme borreliosis (Scheiblhofer et al., 2003).

Mouse Response

  • Host Strain: C3H/HeN
  • Vaccination Protocol: Four-week-old female mice were primed intraperitoneally with 20 μg of each immunogen in 200 μL of complete Freund's adjuvant. Three boosts containing the same amount of immunogen in incomplete Freund's adjuvant were administered at 2, 5, and 8 weeks following the initial injection (Probert and LeFebvre, 1994).
  • Challenge Protocol: Ten days following the final boost, mice received a subcutaneous inoculation containing 107 SON 188 organisms in 100 μl of BSK II medium (Probert and LeFebvre, 1994).
  • Efficacy: Mice immunized with recombinant OspA protein were protected from challenge with Borrelia burgdorferi (Probert and LeFebvre, 1994).

Mouse Response

  • Host Strain: C3H/HeN
  • Vaccination Protocol: Four-week-old female mice were primed intraperitoneally with 20 μg of each immunogen in 200 μL of complete Freund's adjuvant. Three boosts containing the same amount of immunogen in incomplete Freund's adjuvant were administered at 2, 5, and 8 weeks following the initial injection (Probert and LeFebvre, 1994).
  • Challenge Protocol: Ten days following the final boost, mice received a subcutaneous inoculation containing 107 SON 188 organisms in 100 μl of BSK II medium (Probert and LeFebvre, 1994).
  • Efficacy: Mice immunized with recombinant OspB protein were protected from challenge with Borrelia burgdorferi (Probert and LeFebvre, 1994).

Mouse Response

  • Host Strain: C3H/HeN
  • Vaccination Protocol: Four-week-old female mice were primed intraperitoneally with 20 μg of each immunogen in 200 μL of complete Freund's adjuvant. Three boosts containing the same amount of immunogen in incomplete Freund's adjuvant were administered at 2, 5, and 8 weeks following the initial injection (Probert and LeFebvre, 1994).
  • Challenge Protocol: Ten days following the final boost, mice received a subcutaneous inoculation containing 107 SON 188 organisms in 100 μl of BSK II medium (Probert and LeFebvre, 1994).
  • Efficacy: Mice immunized with recombinant OspC protein were protected from challenge with Borrelia burgdorferi (Hanson et al., 1998).

Mouse Response

  • Persistence: A fla mutant is attenuated in SCID mice (Sadziene et al., 1996).
  • Efficacy: A fla mutant induces protection in mice from challenge with wild type B. burgdorferi 28 days after inoculation (Sadziene et al., 1996).
References References References References References References References References
Hanson et al., 2000: Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infection and immunity. 2000; 68(11); 6457-6460. [PubMed: 11035759].
Hanson et al., 2000: Hanson MS, Patel NK, Cassatt DR, Ulbrandt ND. Evidence for vaccine synergy between Borrelia burgdorferi decorin binding protein A and outer surface protein A in the mouse model of lyme borreliosis. Infection and immunity. 2000; 68(11); 6457-6460. [PubMed: 11035759].
   
Probert and LeFebvre, 1994: Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and immunity. 1994; 62(5); 1920-1926. [PubMed: 8168958].
Probert and LeFebvre, 1994: Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and immunity. 1994; 62(5); 1920-1926. [PubMed: 8168958].
Hanson et al., 1998: Hanson MS, Cassatt DR, Guo BP, Patel NK, McCarthy MP, Dorward DW, Höök M. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infection and immunity. 1998; 66(5); 2143-2153. [PubMed: 9573101].
Probert and LeFebvre, 1994: Probert WS, LeFebvre RB. Protection of C3H/HeN mice from challenge with Borrelia burgdorferi through active immunization with OspA, OspB, or OspC, but not with OspD or the 83-kilodalton antigen. Infection and immunity. 1994; 62(5); 1920-1926. [PubMed: 8168958].
Sadziene et al., 1996: Sadziene A, Thompson PA, Barbour AG. A flagella-less mutant of Borrelia burgdorferi as a live attenuated vaccine in the murine model of Lyme disease. The Journal of infectious diseases. 1996; 173(5); 1184-1193. [PubMed: 8627071].